The Amyloidosis Channel is supported with funding from Prothena (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ISA 2022 | Considerations for transplantation in AL amyloidosis
Maximilian Steinhardt, MD, University Hospital Würzburg, Würzburg, Germany, discusses patient eligibility for high-dose chemotherapy and transplantation in AL amyloidosis, highlighting remaining questions in this space. This interview took place at the 2022 International Symposium on Amyloidosis (ISA) held in Heidelberg, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
